A Randomized Phase 2/3 Study of Eryaspase in Combination With Gemcitabine and Carboplatin Chemotherapy Versus Chemotherapy Alone for the Treatment of Patients With Metastatic or Locally Recurrent Triple-Negative Breast Cancer

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 18 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; ERY-ASP (Primary) ; Gemcitabine (Primary)
Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
Focus Proof of concept; Therapeutic Use
Acronyms TRYbeCA-2
Sponsors ERYtech Pharma

Most Recent Events

04 Oct 2023 This trial has been completed in Spain.
12 Sep 2022 According to an ERYtech Pharma media release, The trial's Steering Committee met to review the results of the 25 evaluable patients.
25 May 2022 This trial has been completed in Hungary, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight